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Available online 28 March 2016AMP-activated protein kinase (AMPK) is suppressed in diabetes and may be due to a high ATP/AMP ratio,
however the quantitation of nucleotides in vivo has been extremely difﬁcult. Via matrix-assisted laser desorp-
tion/ionizationmass spectrometry imaging (MALDI-MSI) to localize renal nucleotideswe found that the diabetic
kidney had a signiﬁcant increase in glomerular ATP/AMP ratio. Untargeted MALDI-MSI analysis revealed that a
speciﬁc sphingomyelin species (SM(d18:1/16:0)) accumulated in the glomeruli of diabetic and high-fat diet-
fed mice compared with wild-type controls. In vitro studies in mesangial cells revealed that exogenous addition
of SM(d18:1/16:0) signiﬁcantly elevated ATP via increased glucose consumption and lactate production with a
consequent reduction of AMPK and PGC1α. Furthermore, inhibition of sphingomyelin synthases reversed
these effects. Our ﬁndings suggest that AMPK is reduced in the diabetic kidney due to an increase in the ATP/
AMP ratio and that SM(d18:1/16:0) could be responsible for the enhanced ATP production via activation of the
glycolytic pathway.
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Glycolysis1. Introduction
With the increasing number of diabetic patients, the frequency of
chronic kidney disease (CKD) and end-stage renal disease (ESRD)
continues to increase worldwide (Miyamoto and Sharma, 2013). The
progression of CKD is associated with an increase in hypertension, dia-
betes, and cardiovascular disease (Collins et al., 2010). In spite of recent
advances in the treatment and prevention of both CKD and diabetes, di-
abetic patients remain at high risk for ESRD (Rosolowsky et al., 2011),
and the existing therapies for the diabetic kidney disease are insufﬁ-
cient. To develop breakthroughs for new insights into human diabetic
kidney disease we recently evaluated cohorts of patients with diabetesic Medicine, Center for Renal
go/Veterans Affairs San Diego
h Floor, 9500 Gilman Drive, La
. This is an open access article underwith and without overt kidney disease using a rigorous quantitative
urine metabolomics approach (Sharma et al., 2013). We found that 12
mitochondria-associatedmetabolites were consistently and signiﬁcant-
ly reduced in urine from patients with diabetic kidney disease
compared with patients with diabetes and intact renal function. These
results and the recent recognition of the roles of reduced AMP-
activated protein kinase (AMPK)–PGC1α pathway in diabetic kidneys
from humans and animal models suggested that suppression of AMPK
activity may be a unifying metabolic response to diabetes resulting in
reduced mitochondrial activity, reduced mitochondrial biogenesis, and
organ failure in diabetic kidney disease (Dugan et al., 2013; Kang
et al., 2015). A fundamental question that has emerged is why is
AMPK activity reduced in the diabetic kidney? Although non-invasive
biomarker approaches have providedmany novel insights in our under-
standing toward diabetic kidney disease (Sharma et al., 2013), metabo-
lomics analysis of body ﬂuids will not provide the spatial distribution of
metabolites that could potentially improve our understanding to key
fundamental questions.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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states of caloric depletion (low ATP/high AMP) (Hardie, 2011). Renal
AMPK activity is reduced in the kidneys of humanswith diabetic kidney
disease (DKD), mouse models of DKD (Akita and streptozotocin-
induced diabetic mice), and high-fat diet (HFD)-fed mice (Decleves
et al., 2011; Dugan et al., 2013; Kidokoro et al., 2013). Although stimu-
lation of AMPK has repeatedly been found to be beneﬁcial, the basis
for reduced AMPK activity remains unclear. The most obvious explana-
tion would be that there would be an increase in the ATP/AMP ratio in
the diabetic kidney leading to suppression of AMPK activity. However,
it is extremely difﬁcult to accurately quantitatively and spatially assess
ATP, AMP and ADP in tissues ex vivo since ATP hydrolyzes rapidly during
tissue handling and AMP is of very low abundance. One approach to
address this question is to assess the levels of these nucleotides by
mass spectrometry imaging (MSI) using fresh frozen kidney tissues im-
mediately after harvest.
Recent progress in the ﬁeld of matrix-assisted laser desorption/ion-
ization mass spectrometry imaging (MALDI-MSI) has shed light on un-
derstanding the distribution of analytes in various tissues.MALDI-MSI is
a powerful tool that can determine the distribution of hundreds of ion-
ized analytes based on their molecular masses in a single measurement
and enables the acquisition of multiple images as 2-dimensional (D)
and 3-D ion density maps (Walch et al., 2008; Watrous et al., 2013).
MALDI-MSI enables the visualization of individual molecules on tissue
sections, without antibodies, staining, or complicated pretreatment
steps. Thus, MALDI-MSI may be a suitable tool for investigating the dis-
tribution of analytes in kidney tissues without major processing that
could interfere with relevant in vivo regulation of metabolites. MALDI-
MSI requires amatrix, a small acidic aromatic molecule that absorbs en-
ergy at the wavelength of the irradiating laser (Walch et al., 2008). By
applying matrix onto the tissue sections using either sprayer or subli-
mation, the analytes are extracted from the tissue and form co-
crystalswithmatrix. As the size of the co-crystals is one of the important
determinants of spatial resolution, especially in the high resolution MSI
analysis, particle size of matrix should be as small as possible. In addi-
tion, it is crucial to deposit matrix homogeneously across the tissue
section without any migration of analytes (Collins et al., 2010). The
matrix-coated slide is then submitted to very short laser pulses which
allow optimal desorption and ionization of the analytes, and ionized
analytes are detected and classiﬁed by the difference of mass-to-charge
ratio (m/z) (Walch et al., 2008). It has been reported that MALDI-MSI can
be an applicable method for the accurate quantiﬁcation of nucleotides in
tissue sections (Hattori et al., 2010), thus we applied Fourier transform
ion cyclotron resonance (FTICR)-MALDI-MSI at high spatial resolution to
localize ATP, AMP, and ADP in the kidney microstructure of wild-type
(WT) and diabetic mice. For the screening of metabolites and lipids that
regulate renal nucleotide levels, we performed untargeted MALDI-MSI
followed by the identiﬁcation by the ambient ionization interfaced with
a microscope and mass spectrometry (AMM). We demonstrated that
one of the sphingomyelin (SM) species may play a key role in the regula-
tion of ATP levels and the AMPK pathway.
2. Material and Methods
2.1. Materials
Cell culture and transfection regents were purchased from Life tech-
nologies (Grand Island, NY). p-AMPKT172 and AMPKα antibodies were
purchased from Cell Signaling Technology (Danvers, MA). ASM (H-
181), N-SMase2 (H-195), SMS1 (H-130) (for immunohistochemistry),
SMS2 (N-13), Smad3 (38-Q), TGFβ1 (V) and rabbit anti-goat IgG-HRP
antibodies were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA). SGMS1 (SMS1) antibody for western blot was purchased
from Aviva Systems Biology (San Diego, CA). Anti-PGC1α and anti-
Smad3 (phospho S423 + S425) antibodies were purchased from
Abcam (San Francisco, CA). Monoclonal anti-actin antibody waspurchased from Sigma-Aldrich (St. Louis, MO). Biotin-XX goat anti-
rabbit IgG (H + L) were purchased from Life technologies. Donkey
anti-rabbit IgG-HRP and sheep anti-mouse IgG-HRP antibodies, and all
siRNAs were purchased from GE Healthcare (Chicago, IL, USA). 2-
Deoxy-D-glucose (2-DG) was purchased from Sigma-Aldrich.
2.2. Animal Studies
All mice were purchased from Jackson Laboratory (Bar Harbor, ME).
Mice were given standard rodent chow and water ad libitum. To study
the effect of high fat diet, 7-week-old male C57BL/6J mice were fed a
HFD (60% of total calories from fat, 20% protein, 20% carbohydrate) (Re-
search Diets, New Brunswick, NJ) or standard diet (STD) (5% fat, 24.5%
protein) for a period of 1 week before harvesting kidneys. For the mea-
surement of plasma SM(d18:1/16:0), six-week-old male C57BL/6J mice
were fed a HFD or STD for a period of 14weeks before being euthanized
at 20 weeks of age. To study the effect of type 1 diabetes, male diabetic
Akita (C57BL/6J-Ins2Akita) mice and age-matched C57BL/6J WT mice
were studied at 23 week-aged. Mice were euthanized by cervical dislo-
cation. All animal studies were approved by the Institutional Animal
Care and Use Committee of University of California, San Diego.
2.3. Human Subjects
Normal kidney tissues were obtained from fresh tissues obtained
from renal cell cancer nephrectomy specimens and only non-involved
portions renal cell cancer were used. The signed informed consent
was obtained from human subjects and the study protocol was ap-
proved by the institutional review board from the University of
Pennsylvania.
2.4. FTICR-MALDI-MSI for Nucleotide Analysis
Kidney tissues were obtained from 23 week-aged male diabetic
Akita (C57BL/6J-Ins2Akita) mice and age-matched C57BL/6J control
mice (n = 3/group). Snap frozen kidneys were quickly embedded in
carboxymethyl cellulose (CMC) and sectioned (10 μm), and then thaw
mounted onto an ITO glass slide. 9-AA (9-aminoacridine) (10 mg/mL
in MeOH) was used as a MALDI matrix and applied by the SunCollect
System (SunChrom, Friedrichsdorf, Germany). Just after matrix applica-
tion, FTICR-MALDI-MSI was performed in negative ion mode using a
SolariX MALDI-FTICR 7.0T Mass Spectrometer (Bruker Daltonics, MA)
equipped with a Smartbeam II laser used at a repetition rate of 1 kHz.
Mass spectrawere acquired in the100–700m/z range in negative detec-
tion mode. The mass spectrum obtained for each position of the images
corresponds to the averagedmass spectra of 300 consecutive laser shots
on the same locationwith a time domain of 1MWord, subsequent single
zero ﬁlling and sinewave apodization. An ICR noise threshold was ﬁxed
at 0.97 for imaging acquisition. Two image raster sizes were selected for
whole kidney imaging at 70 μm and for high spatial resolution imaging
of glomerular region at 30 μm. FTMSControl 3.0 and FlexImaging 3.2
software packages (Bruker Daltonics, Bremen, Germany) were used to
control the mass spectrometer and set imaging parameters. The visual-
ization and statistical analysis of imaging data were performed using
MultImaging 1.0 software (ImaBiotech, Lille, France). For the detection
of glomeruli, the localization of a phosphatidic acid (PA (36:1)) was
used as a contrast ion as described previously by (Grove et al. (2014),
and regions of interest (ROIs) for glomeruli were drawn on the MS im-
ages. Fifteen glomeruli per animalwere used for the analysis. For the de-
termination of cortical tubular and medullary regions,
phosphatidylinositol (PI (40:4)) and sulfatide (ST 42:1 (OH)) were
used as contrast ions, respectively (Muller et al., 2015). Periodic acid-
Schiff (PAS) staining was performed on adjacent section of each fresh
kidney tissue used for MALDI imaging acquisition and scanned using a
40× magniﬁcation objective on an Olympus IX18 microscope (Olym-
pus, Germany). Scanswere then integrated in theMultImaging software
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bution of molecular species with kidney histological regions.
2.5. Sample Preparation and MALDI-MSI Analysis
Kidney samples for MALDI-MSI were prepared and analyzed as pre-
viously described (Rath et al., 2012) with slight modiﬁcations. Brieﬂy,
frozen mouse kidney (−80 °C) was cut in half, and a small piece
(~1 cm) of human kidney cortex was cut out from surface of the frozen
human kidney. These tissues were afﬁxed to the chuck in a Leica
CM1850 cryostat with a minimal amount of O.C.T. (Sakura Finetek, Tor-
rance, CA). To avoid O.C.T. signals, O.C.T. was used as a glue and did not
touch the regions that were being sectioned. Twelve μm thick sections
were afﬁxed to cold ITO-coated conductive glass slides (Bruker
Daltonics). Sample slides were then placed in a vacuum desiccator
above a bed of fresh dry-rite. The desiccator was kept cold in a cooler
of dry ice, which was allowed to evaporate over 12 h. The samples
were dried for an additional 12 h after the dry ice had evaporated. Sam-
ple slides were then coated with 2,5-dihydroxybenzoic acid (DHB)
(Sigma-Aldrich, St. Louis, MO). DHB was applied in a sublimation
chamber at 50 Torr for 9 min at 110 °C. Samples were rehydrated in a
humidity chamber at 45 °C for 3 min. Two mice were examined from
each sample condition, and only results common across both animals
were reported. MALDI-MSI experiments were performed on a Bruker
Autoﬂex Speed TOF/TOF instrument. Mass calibration and tuning was
performed with a Peptide calibration standard (Bruker Daltonics) in
the quadratic mode. For general analysis (reﬂectron positive mode),
the following settings were used: raster width 90 μm, laser size large,
laser offset 62%, laser range 38%, laser power 63%, laser frequency
500 Hz (tissue sections), laser summed shots 256 total at 32 shots on
randomwalk, mass rangem/z 0 tom/z 4000. For high resolution analy-
sis (reﬂectron positive mode), the following settings were used: raster
width 25 μm, laser size large, laser offset 62%, laser range 38%, laser
power 70%, laser frequency 125 Hz (tissue sections), laser summed
shots 32 total at 16 shots on random walk, mass range m/z 0 to m/z
4000. Data analysis was performed in Bruker Daltonics FlexImaging
3.0. For the detection of glomeruli, the sections used for MALDI-
imaging acquisition were stained with hematoxylin and eosin (H&E)
and then examined by a BZ-9000 microscope (KEYENCE, Itasca, IL).
2.6. AMM Analysis
Ambient ionization interfaced with a microscope and mass spec-
trometry (AMM) were used for the identiﬁcation of lipids as previously
described in detail (Hsu et al., 2013). Using this approach, we were able
to obtainMS andMS/MS data for in situmolecular identiﬁcation. Brieﬂy,
nanoDESI is set up on the same x–ymovable platform that is used to po-
sition the microscope. The fused silica capillary tubes of the nanoDESI
are mounted on the independent x–y–z linear actuator for accurate
alignment. The conjunct terminals of the two capillary tubes are
ﬂame-pulled to shrink the size of the capillary to ∼60 μm (outer diame-
ter). The sample was placed steady on a z-axis actuator, which is ﬁxed
onto the x–y stage of the microscope that is used to adjust the coordi-
nate of the sample (relative to the nanoDESI liquid junction). The instru-
ment was ﬁrst tuned tom/z 816.3 using 2 μMbovine cytochrome c 0.1%
formic acid aqueous solution. Ion spectra were recorded in real-time
once the contact was made between samples and liquid junction.
High-resolution FTICR-MS detection was performed using a maximum
ion accumulation time of 4000 ms, with an average of 100–1000 ms
per scan at 50,000 resolution. At a ﬂow rate on a milliliter per minute
scale, MS signals from molecules on the tissue sections decay within a
few minutes; therefore this relatively lower resolution was selected
for faster scan. A 1000 ms maximum ion accumulation time was used
for low-resolution linear trap quadrupole (LTQ) detection. The top-
down MS/MS analysis was performed using a collision energy of 30%
and an activation Q of 0.200 for both LTQ (isolation Δm/z = 3) andFTICR (isolation Δm/z= 8) detections. MS/MS ion intensity of multiple
sample points was accumulated to increase the signal-to-noise ratio.
Identiﬁcation of lipidswas assistedwithmetabolomic and lipidomic da-
tabases, including METLIN (Smith et al., 2005) and LIPID MAPS (Fahy
et al., 2007).
2.7. Quantiﬁcation of Glomerular Size and Mesangial Matrix
PAS-stained sections were analyzed as described previously with
slightmodiﬁcations (Miyamoto et al., 2012). To evaluate the glomerular
size and mesangial matrix area, 15 randomly selected glomeruli were
analyzed using i-solution software (Advanced Imaging Concepts,
Princeton, NJ). Quantitative analysis was performed in a blinded
manner.
2.8. Procedures for Immunohistochemistry
ASM (aSMase), N-SMase2, SMS1, SMS2 immunoperoxidase staining
were performed using the method as described previously (Miyamoto
et al., 2012). As primary antibodies, polyclonal antibody against ASM
(1:500), N-SMase2 (1:500), SMS1 (1:500) and SMS2 (1:500) were ap-
plied for 12 h at 4 °C, and biotin-XX goat anti-rabbit IgG (H + L)
(1:200) or biotin-XX rabbit anti-goat IgG (H+L) (1:200) secondary an-
tibody were applied for 1 h at room temperature. To evaluate
intraglomerular ASM, N-SMase2, SMS1 and SMS2 positive cells, we ex-
amined 15 randomly selected glomeruli per mouse (n = 3/group)
under high magniﬁcation (×400). Quantitative analysis for all staining
was performed in a blinded manner.
2.9. Cell Culture
The present studies were performed with a murine mesangial cell
(MMC) line, as previously described (Ziyadeh et al., 1994). Cells were
originally isolated from kidneys of SJL/J(H-2s) normal mice and trans-
formed with non-capsid-forming Simian Virus 40 to establish a perma-
nent cell line (Wolf et al., 1992). Cells were cultured at 37 °C with 5%
CO2/95% air and maintained in Dulbecco's modiﬁed essential medium
(DMEM) containing 5.5mMD-glucose, 10% FBS, 100 units/mLpenicillin,
100 mg/mL streptomycin, and 2 mM supplemental glutamine. Cells
were passaged every 72 h. For western blot studies, MMCs were plated
in 10 cmcell plates, after 50% conﬂuence, the cell culturemediawere re-
placed with serum-free DMEM, and then incubated for 24 h before ad-
dition of liposome or vehicle solutions. For ATP measurements, MMCs
were plated in 96-well cell plates, after 50% conﬂuence, the cell culture
media were replaced with serum-free DMEM, and then incubated for
24 h before addition of liposome solutions. Glucose, lactate and L-
glutamine levels were measured by the 2900 Biochemistry Analyzer
(YSI Inc. Yellow Springs, OH).
2.10. siRNA Transfection of MMCs
Transfection of MMCs with SMS1 and SMS2 siRNA was performed
using a Lipofectamine RNAiMAX transfection reagent according to the
manufacturer's instructions. Brieﬂy, MMCs were plated in 96-well (for
ATP measurement) or 6-well (for immunoblot) cell plates, after 30–
40% conﬂuence, MMCs were washed with Dulbecco's Phosphate-
Buffered Saline (DPBS) and transfected with different siRNAs in
serum-free DMEM. A negative control siRNA pool, which does not inter-
fere with any known cellular mRNA was used simultaneously. After in-
cubation with each siRNA (25 nM) solution for 24 h, MMCs were
washed and treated with liposomes or vehicle, then incubated in
serum-free DMEM for additional 24 h. At 48 h after transfection of
siRNAs, MMCs in 96-well plate were used for ATP measurement and
MMCs in 6-well plates were harvested for immunoblot.
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1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-
dioleoyl-3-trimethylammonium-propane, chloride salt (DOTAP),
and N-palmitoyl-D-erythro-sphingosylphosphorylcholine (SM(d18:1/
16:0)) were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL,
USA). 1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine iodide
(“DiR”; DiIC18(7)) was purchased from Invitrogen (Eugene, OR, USA)
and used for the efﬁcient delivery of SM into cells (Kleusch et al.,
2012). Liposomes were prepared as previously described with slight
modiﬁcations (Kleusch et al., 2012). Brieﬂy, DOPE, DOTAP, DiR and SM
were mixed in chloroform in a weight ratio of DOPE/DOTAP/DiR/
SM of 1/1/0.02/0.08. The mixture without SM was also prepared for
control liposome. Lipid mixtures were dried under a gentle stream
of nitrogen, and then remaining chloroform was completely evapo-
rated under a vacuum for 12 h. Lipids were then hydrated with
20 mM HEPES buffer (Sigma-Aldrich) and ﬁnal SM concentration
was adjusted to 0.08 mg/mL (ﬁnal DiR concentration; 0.02 mg/mL).
The solution was vortexed for 5 min, and then sonicated in a bath
sonicator for 20 min to make liposome stock solutions. For mem-
brane fusion experiments, liposome stock solution was diluted
1:100 with serum-free DMEM medium, and then incubated with
MMCs for 15 min at 37 °C. Subsequently, the fusion mixture was re-
placed by fresh serum-free DMEM medium. At 24 h after incubation
with liposome whole cell protein was isolated.2.12. Immunoblotting
Cell lysates were prepared using RIPA buffer (Cell signaling) accord-
ing to the manufacturer's instructions. Total protein concentration was
determined using BCA Protein Assay Kit (Life technologies). Thirty mi-
crogramprotein perwell were loaded on a 4–12% Bis-Tris Gel (Life tech-
nologies) and transferred to a nitrocellulose (Life technologies) or PVDF
(EMDMillipore, Billerica,MA)membrane. The blotwas blockedwith 5%
nonfat dry milk (Cell signaling) and incubatedwith primary antibod-
ies at 4 °C for overnight. Then, secondary antibodies were applied
and the signals were developed with SuperSignal™ West Pico
Chemiluminescent Substrate (Life technologies). As primary anti-
bodies, anti-pAMPKα, AMPKα, ASM (H-181), TGFβ1 (V) and SMS2
(N-13) were used at 1:500 dilution. Anti-SGMS1 (SMS1), p-Smad3,
Smad3 (38-Q) and PGC1α were used at 1:1000 dilution. Anti-β-
actin was used at 1:2500 dilution.2.13. Phenol–chloroform Extraction of Nucleotides From Kidney Cortex
Nucleotide extraction was performed as previously described with
minor modiﬁcations (Chida and Kido, 2014). In brief, 50 mg of freshly
excised kidney cortex (outside one-third of the kidney) was minced
into ﬁne pieces with a razor blade and homogenized in 3 mL ice-cold
Phenol-TE saturated (Sigma). The homogenate (500 μL) was combined
with chloroform (200 μL) andwater (150 μL), vortexed and centrifuged
at 15,000g for 10 min. The aqueous layer containing nucleotides was
separated carefully and frozen at −80 °C until further use. Samples
were dilutedwithwater (1:50) andDNA concentrationwas determined
prior to quantiﬁcation of adenine nucleotide content.Fig. 1.Targeted FTICR-MALDI-MSI analysis reveals the increasedATP, ATP/AMP andATP/ADP in
and AMP (red rectangle), ADP (yellow rectangle) and ATP (green rectangle)-related peaks. (B–D
(E and F) Representative FTICR-MALDI-MSI images for AMP, ADP and ATP of WT (E) and Ak
phosphatidylinositol (PI (40:4)) and phosphatidic acid (PA (36:1)) were used as contrast ion
side shows representative images of PAS-stained kidney sections and the border between co
for PA (36:1), AMP, ADP and ATP at a spatial resolution of 30 μm. Glomerular area was guide
Rainbow color scales was used. The white color represents the highest signal intensity (10
Quantitative results for ATP (H), AMP (I), ADP (J), and ATP/AMP (K) and ATP/ADP (L) ratio. Fi
are the means ± SE. **P b 0.01 and *P b 0.05.2.14. ATP and ADP Measurement
ATP and ADP levels weremeasured by ApoSENSOR™ ADP/ATP Ratio
Bioluminescence Assay Kit (BioVision, Inc., Milpitas, CA) according to
the manufacturer's instructions.2.15. SM Analysis for Renal Venous and Arterial Plasma Samples
Male C57BL/6J mice fed a HFD or STD for 14 weeks were used. At
time of harvest (20 week-age), blood samples were drawn from the
carotid artery under anesthesia and plasma samples were collected.
Plasma SM(d18:1/16:0) levels were analyzed on an AB SCIEX QTRAP
5500 triple quadrupole mass spectrometer equipped with a Turbo V
electrospray ionization (ESI) source, Shimadzu LC-20A UHPLC system,
and a PAL CTC autosampler. The chromatographic peakswere identiﬁed
using MultiQuant (v2.1.1, AB Sciex), conﬁrmed by manual inspection,
and the peak areas integrated. Themedian of the peak area of stable iso-
tope internal standardswas calculated andused for the normalization of
metabolite concentrations across the samples and batches. n = 5 per
group. Data were log-transformed prior to multivariate and univariate
analysis.2.16. Statistics
Data are expressed as means ± SE. ANOVA or student's t-test were
used to analyze data, P b 0.05 considered statistically signiﬁcant.3. Results
3.1. FTICR-MALDI-MSI Revealed That ATP/AMPRatio is Increased in the Glo-
meruli of Diabetic Mice
Nucleotides from renal cortex samples were initially performed by
phenol chloroform extraction and measured ATP and ADP levels in the
renal cortical tissues of normal and diabetic mice. The ATP/ADP ratio
was signiﬁcantly increased in the renal cortex of diabetic mice (Fig.
S1A–C). However, this method of measuring adenylate nucleotides is
not suitable for glomerular measurements as themethod to isolate glo-
meruli from mice is time-consuming and requires multiple steps
(Takemoto et al., 2002). To deﬁnitively assess the relative ATP/ADP or
ATP/AMP ratios in the glomeruli of diabetic mice, we performed high-
mass resolution FTICR-MALDI-MSI. To minimize the hydrolysis of
renal adenylate nucleotides, kidneys were removed immediately after
cervical dislocation and snap frozen in liquid nitrogen followed by
mounting on ITO glass slides and matrix (9-AA) application. ATP, AMP
and ADP were identiﬁed by MS (Fig. 1A) and MS/MS (Fig. 1B–D) and
found to be widely distributed throughout the kidney at a spatial reso-
lution of 70 μm (Fig. 1E and F). Relative quantitation and visualization
of glomerular ATP, AMP, and ADP were achieved by analysis with
high-spatial resolution (30 μm; Fig. 1G). Interestingly, glomerular ATP
was signiﬁcantly increased by 59.3% and AMP was decreased by 61.4%
in the glomeruli of diabeticmice as compared to non-diabetic glomeruli
(Fig. 1H and I). Thus, the glomerular ATP/AMP and ATP/ADP ratios were
increased by 175.1 and 313.1%, respectively, in the glomeruli of diabetic
mice (Fig. 1K and L).the glomeruli of Akitamice. (A) Representative overall averageMS1 spectrumof the kidney
) RepresentativeMS/MS spectra and chemical structures of AMP (B), ADP (C) and ATP (D).
ita (F) mice at a spatial resolution of 70 μm. The distribution of sulfatide (ST 42:1(OH)),
s for medullary, cortical tubular and glomerular regions, respectively. Images on the left
rtex and medulla is shown by dotted lines.(G) Representative FTICR-MALDI-MSI images
d by PA (36:1) content and the outlines of glomeruli were shown by red dotted circles.
0%) and the black color represents the lowest signal (0%) of the particular ion. (H–L)
fteen randomly selected glomeruli per mouse were examined (n= 3/per group). Values
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We next performed untargeted MALDI-MSI in the kidney tissues to
identify analytes whichmay potentially regulate ATP production in kid-
ney tissues.We ﬁrst performedMALDI-MSI analysis (spatial resolution;
90 μm) using kidney sections of normal mice and screened the analytes
in kidney tissues. DHB was used as a MALDI matrix. We picked upm/z
valueswhich have an obvious peak in the spectrum and a clear distribu-
tion in the kidney section. m/z values with high background intensity
were excluded as thesem/z values may contain the signal from matrix
itself. Based on a total of 2 normal mouse kidney sections, we found a
total of 270 m/z values distributed in the kidney section. 151 of 270
m/z value were distributed speciﬁcally in renal compartments such as
cortex and medulla and 72 m/z values were distributed throughout
the kidney section. Each blue triangle in Fig. S2C shows selected peak,
and Fig. S2D showedMSI images in representativem/z values. One hun-
dred and twenty two out of 270m/z valueswere distributed in the renal
cortex (red triangles in Fig. S2C). MSI images exhibited several different
distribution patterns in renal cortex (Fig. S2E). For example, peaks with
m/z of 192.8, 701.6, 744.7, and 772.7 were distributed throughout the
renal cortex whereas peaks with m/z of 683.6, 703.6, 725.6, and 741.5
m/zwere distributed primarily in the corticomedullary junction. Twen-
ty nine out of 270m/z values were distributed in renal medulla (green
triangles in Fig. S2C). MSI images also exhibited speciﬁc distribution
patterns in renal medulla (Fig. S2F). Fig. S2G–J shows representative
m/z values with speciﬁc distribution in the renal compartments and
Fig. S2K shows the merged image.
3.3. Distribution of Analytes in Human Kidney
We also examined the cortical sections of normal human kidney to
compare the distribution of analytes, which were detected in the renal
cortex of mice. We attempted to identify peaks with preferential distri-
bution in the glomeruli asmany common kidney diseases initially man-
ifest in glomeruli. Fig. 2A is a representative of human kidney section
coated with DHB matrix. After MSI analysis, the same section was re-
evaluated histologically by H&E staining to identify glomeruli in kidney
section (Fig. 2B and C).We identiﬁed peakswithm/z of 703.6, 725.6 and
741.5 to have scattered glomerular type distribution in the human kid-
ney cortex (Fig. 2D–G).We found that these analytes were preferential-
ly distributed in the glomeruli (Fig. 2H–J; white arrows). Interestingly,
all of these analytes (m/z of 703.6, 725.6 and 741.5) were distributed
not only in the glomeruli but also in the vascular wall of the human kid-
ney (Fig. 2E–G; yellow arrows). Although these analyteswere also pres-
ent in themouse kidney, the spatial resolution (90 μm)was insufﬁcient
to deﬁnitively evaluate the distribution in the renal cortex usingMALDI-
MSI (Fig. S2E).
3.4. Detection and Identiﬁcation of Analytes in Glomeruli of Mouse and
Human
For the accurate detection of analytes in the mouse glomeruli, we
performed untargeted high-spatial-resolution (HSR)-MALDI-MSI anal-
ysis (spatial resolution: 25 μm) using human and mouse kidney sec-
tions. After MSI analysis, the same section was re-evaluated by H&E
staining (Fig. 2M). Fig. 2K and L showed the average spectra obtainedFig. 2. High-spatial-resolution (HSR)-MALDI-MSI and AMM enables to identify SM as a glome
kidney section. Bar; 1 mm. (B and C) Representative H&E image of human kidney secti
(D) Representative overall average spectrum of human kidney obtained by MALDI-MSI an
glomeruli. (E–G) MALD-MSI images of human kidney at m/z 703.6, 725.6 and 741.5, respec
Spatial resolution for MALDI-MSI images (E–J); 90 μm. (K and L), Representative overall a
resolution (HSR)-MALDI-MSI analysis. Red arrows indicate the peaks (analytes) which are m
H&E-stained images and correspondent HSR-MALDI-MSI images (at m/z 703.6, 725.6 and 74
Spatial resolution for HSR-MALDI-MSI images; 25 μm. (N) Chemical structure of SM(d18:1/16
K+ adduct (Q) of SM(d18:1/16:0). Samples were directly collected from the glomeruli in the kfromHSR-MALDI-MSI of human kidney (Fig. 2K) andmouse kidney sec-
tions (Fig. 2L), respectively, and the red arrows identify the peaks of
analytes which are mainly distributed in the glomeruli. At m/z 703.6,
725.6 and 741.5, the analytes were distributed primarily in the human
glomeruli (Fig. 2M; white arrows) compared with nearby regions. In
mouse glomeruli, a similar distribution pattern was observed at the
samem/z values (Fig. 2M; white arrows). Based on the accurate parent
masses determined by high resolution FTICR MS and their subsequent
MS/MS (AMM analysis), molecules at m/z 703.5775 (H+ adduct;
Fig. 2O), 725.5581 (Na+ adduct; Fig. 2P) and 741.5335 (K+ adduct;
Fig. 2Q) were annotated as sphingomyelin (SM). Since 18 carbon
atoms are typically present in the long chain sphingoid bases (LCB) in
mammals (Sullards et al., 2011), we identiﬁed that the detected SM is
most likely SM(d18:1/16:0) (Fig. 2N). These sets of featureswere highly
expressed in both mouse and human glomeruli.3.5. Accumulation of SM(d18:1/16:0) in the Glomeruli of Type 1 Diabetic
and High-fat-fed Mice
We then applied HSR-MALDI-MSI to determinewhether glomerular
SM(d18:1/16:0) was differentially regulated between type 1 diabetic
mice and control mice. At 23 weeks of age, HbA1c and relative kidney
weight (mg/g body weight) were signiﬁcantly increased and body
weight was signiﬁcantly decreased in diabetic mice (Table 1). Glomeru-
lar size, mesangial matrix and urinary albumin to creatinine ratio were
signiﬁcantly increased in Akita mice (Fig. S3A, C, D and G). Fig. 3A and B
shows the average spectra obtained from HSR-MALDI-MSI of the kid-
neys from WT and Akita mice, respectively. Interestingly, HSR-MALDI-
MSI showed that SM(d18:1/16:0) was more abundant in the glomeruli
of diabetic mice compared with WT mice (Fig. 3C). We further exam-
ined HSR-MALDI-MSI to explore the accumulation of SM(d18:1/16:0)
in an obesity animal model of CKD. Since we previously showed that
one week of HFD feeding is associated with reduced glomerular AMPK
activity (Decleves et al., 2011), mice were fed with standard diet
(STD) or HFD for one week and euthanized. Fig. 4A and B shows the av-
erage spectra obtained from HSR-MALDI-MSI of the kidneys from STD-
and HFD-fed mice, respectively. There was no difference in glomerular
size, mesangial matrix between STD-fed and HFD-fed mice after just
one week of the high fat diet indicating that structural damage had
not yet occurred (Fig. S3B, E, F and H). However, as with the diabetic
mice, HFD-fed mice showed accumulation of SM(d18:1/16:0) in the
glomeruli compared with STD-fed mice (Fig. 4C), suggesting that one
week of high-fat feeding is sufﬁcient to accumulate SM in the glomeruli.
Independent studies were performed to measure SM(d18:1/16:0) con-
centration in arterial and renal venous plasma samples obtained from
20-week aged STD-fed and HFD-fed mice (duration of HFD; 14 weeks)
to conﬁrm whether SM(d18:1/16:0) was synthesized in the kidney
and released into the bloodstream. Fig. S4A–C shows body weight,
blood glucose and relative kidney weight at 20-week age. Interest-
ingly, renal venous SM(d18:1/16:0) was increased in HFD-fed
mice compared with STD-fed mice (Fig. 4D). In addition, the
ΔSM(d18:1/16:0) across the renal vascular bed, which may indicate
the amount of SM(d18:1/16:0) secretion from the kidney, was also
signiﬁcantly increased in HFD-fed mice compared with STD-fed
mice (Fig. 4D).rular-localized lipid in mouse and human kidney. (A) Representative DHB-coated human
on (B) and magniﬁed H&E image (C). Black arrows indicate glomeruli. Bar; 1 mm.
alysis. Red arrows show peaks (analytes) which are mainly distributed in the human
tively. (H–J) Overlay images of H&E and MSI images. White arrows indicate glomeruli.
verage spectra of human kidney (K) and mouse kidney (L) obtained by high-spatial-
ainly distributed in the glomeruli of both mouse and human kidney. (M) Representative
1.5) of human and mouse kidneys. Scale bars; 200 μm. White arrows indicate glomeruli.
:0). (O–Q) MS/MS (left) and FT-MS (right) spectra of H+ adduct (O), Na+ adduct (P) and
idney sections by the AMM instrument equipped with the light microscopy.
Fig. 3.Accumulation of SM(d18:1/16:0) in the glomeruli of Akitamice. (A and B) Representative overall average spectra obtained from the kidney sections ofWT (A) andAkita (B)mice by
HSR-MALDI-MSI analysis. Black or red triangles indicate the SM(d18:1/16:0) related peaks (m/z 703.6 and 741.5). (C) Representative SM(d18:1/16:0) HSR-MALD-MSI images of the
kidney cortex of WT and Akita mice. White arrows indicate glomeruli. Glomerular area was guided by H&E staining and the outlines of glomeruli in the enlarged images were shown
by red dotted circles. Spatial resolution for HSR-MALDI-MSI images; 25 μm.
Table 1
Metabolic characteristics of mice.
Group n Age (weeks) Body weight (g) Blood glucose (mg/dL) HbA1c (%) Kidney weight/body weight (mg/gBW)
Wild type 11 23 29.6 ± 0.50 129 ± 7.9 4.2 ± 0.10 11.7± 0.43
Akita 6 23 23.7 ± 0.31⁎⁎⁎ 558 ± 19.9⁎⁎⁎ 12.2 ± 0.48⁎⁎⁎ 19.4± 0.57⁎⁎⁎
Group n Age (weeks) Body weight (g) Blood glucose (mg/dL) HbA1c (%) Kidney weight/tibia (mg/mm)
STD 9 8 23.6 ± 0.63 154 ± 7.3 4.2 ± 0.10 13.9± 0.31
HFD 11 8 26.5 ± 0.48⁎⁎ 181 ± 12.3 4.4 ± 0.02 14.8± 0.59
Data are means ± SE.
⁎⁎ P b 0.01 vs. STD.
⁎⁎⁎ P b 0.001 vs.wild type.
Fig. 4. Accumulation of SM(d18:1/16:0) in the glomeruli of HFD-fed mice. (A and B) Representative overall average spectra obtained from the kidney sections of standard diet (STD) (A)
and high-fat diet (HFD)-fed (B) mice by HSR-MALDI-MSI analysis. Duration of HFD feeding; one week. Black or orange triangles indicate the SM(d18:1/16:0) related peaks (703.6 and
741.5 m/z).(C) Representative SM(d18:1/16:0) HSR-MALD-MSI images of the kidney cortex of STD- and HFD-fed mice. White arrows indicate glomeruli. Glomerular area was guided
by H&E staining and the outlines of glomeruli in the enlarged images were shown by red dotted circles. Spatial resolution for HSR-MALDI-MSI images; 25 μm. (D) Arterial and renal
venous plasma SM(d18:1/16:0) ratios in STD and HFD-fed mice. Duration of HFD feeding; 14 weeks. n= 5 per group. ***P b 0.001 and *P b 0.05.
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130 S. Miyamoto et al. / EBioMedicine 7 (2016) 121–1343.6. Dysregulation of SM Synthase and SMase in the Glomeruli of Akita and
HFD Mice
To explore the mechanisms for SM(d18:1/16:0) accumulation in the
glomeruli, we performed immunohistochemical staining for SM synthase
(SMS) and sphingomyelinase (SMase). Both SMS1 and SMS2 expression
were signiﬁcantly increased in the glomeruli of diabetic mice compared
with WT mice (Fig. 5A and B), while no change was observed in SMase
expression (Fig. 5C and D). SMS1 expression was signiﬁcantly increased
and neutral SMase2 (nSMase2) was signiﬁcantly reduced in theFig. 5. Expression of sphingomyelin synthases (SMSs) and sphingomyelinases (SMases) in the
and F) aSMase (C andG), nSMase2 (D andH)-stained glomerular pictures (400×magniﬁcation)
(I and J) Schematic diagram of accumulation of SM and role of SM-related enzymes in the kidn
examined (n= 3/per group). Values are the means ± SE. ***P b 0.001 and **P b 0.01.glomeruli of mice fed for 1 week with the HFD compared with STD-fed
mice (Fig. 5E and H). These results suggest that insufﬁciency of SMase
and/or stimulation of SMS may contribute to the accumulation of
SM(d18:1/16:0) in glomeruli of diabetic and HFD-fedmice (Fig. 5I and J).
3.7. Inhibition of AMPK Activity by SM in Cultured Mesangial Cells
In the human kidney, the MSI data showed that SM(d18:1/16:0) is
clearly distributed in the vascular wall (yellow arrows in Fig. 2E–G;
possibly in smooth muscle cells) as well as glomeruli (Fig. 2E–G). Asglomeruli of Akita and HFD-fed mice. (A–H) Representative, SMS1 (A and E) and SMS2 (B
. (A–D)WT vs.Akitamice. (E–H) STD vs.HFD-fedmice. Duration of HFD feeding; oneweek.
ey of Akita (I) and HFD-fed (J) mice. Fifteen randomly selected glomeruli per mouse were
131S. Miyamoto et al. / EBioMedicine 7 (2016) 121–134mesangial cells are similar to vascular smoothmuscle cells in bothmor-
phology and function (Iehara et al., 1996), we speculated that
SM(d18:1/16:0) may play a role in the mesangial cells of the glomeruli
in regulating key pathways (AMPK/PGC1α) linked to diabetic and obe-
sity related kidney disease (Decleves et al., 2011; Dugan et al., 2013).
We therefore investigated the effect of liposomal SM(d18:1/16:0) inFig. 6. SM(d18:1/16:0) regulates ATP production via glycolysis inmurinemesangial cells (MMCs
p-AMPKα (C). (D–G) Representative western blot images (D) and quantitative results of aS
quantitative results of p-Smad3 (I) and TGFβ1 (J). MMCs were treated with different liposome
analysis. n= 4/per group. (K) Representative western blot images of SMS1, SMS2 and actin. (L
with different liposomes. (MandN) Representativewestern blot images (M) and quantitative re
(per 24 h) inMMCs. (Q) Glutamine levels in the medium of MMCs. (R) ATP levels inMMCs. MM
n= 6–12 per group. Representative results from three independent experiments are shown. Vmurine mesangial cells (MMCs). Treatment of MMCs with liposomal
SM(d18:1/16:0) signiﬁcantly reduced AMPK activity and PGC1α pro-
tein expression in MMCs (Fig. 6A–C). It is noteworthy that SM(d18:1/
16:0) not only reduced acid SMase (aSMase) expression but also in-
creased SMS2 expression, suggesting the potential for a SM self-
ampliﬁcation loop in MMCs (Fig. 6D–G). TGF-β1 protein levels showed). (A–C)Representativewestern blot images (A) and quantitative results of PGC1α (B) and
Mase (E), SMS1 (F), and SMS2 (G). (H–J) Representative western blot images (H) and
s for 15 min, and then cultured for 24 h before harvest. Whole cell lysates were used for
) ATP levels in MMCs. MMCs were transfected with SMS1 and/or SMS2 siRNA and treated
sults of p-AMPKα (N). (O) Glucose consumption (per 24h) inMMCs. (P) Lactate secretion
Cs were treated with or without 2-DG (10mM) for 1 h before ATP measurement. L, O–R;
alues are means ± SE. ***P b 0.001. **P b 0.01 and *P b 0.05.
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cant (Fig. 6H and J). However, liposomal SM(d18:1/16:0) exhibited a
signiﬁcant increase in Smad3 phosphorylation compared with control
liposome (Fig. 6H and I), indicating that the ﬁbrosis pathway was en-
gaged by SM.
3.8. SM(d18:1/16:0) Regulates ATP Production in Cultured Mesangial Cells
The depletion of SMS1, accompaniedwith reduction of SM, has been
recently shown to inhibit high glucose-induced ATP production in mu-
rine islet cells (Yano et al., 2011). As SM may be linked to regulation of
ATP production and SM regulates AMPK and PGC1α, we examined the
effect of SM(d18:1/16:0) on ATP levels with or without the silencer
siRNAs targeting SMS1 and SMS2 in MMCs. Transfection with siRNAs
targeting SMS1 or SMS2 signiﬁcantly downregulated the expression
level of SMS1 and SMS2 (N70% and N80% respectively), as measured
by western blotting (Fig. 6K). ATP production was slightly reduced by
either SMS1 or SMS2 siRNA but not signiﬁcantly (Fig. 6L). However,
co-transfection with both SMS1 and SMS2 siRNA signiﬁcantly reduced
ATP production comparedwith the control siRNA group (Fig. 6L). Treat-
ment with liposomal SM(d18:1/16:0) signiﬁcantly increased ATP pro-
duction and was prevented by SMS2 or SMS1 + 2 siRNA (Fig. 6L). It is
noteworthy that the knockdown of either SMS1 or SMS2 markedly in-
creased AMPK activity compared with the control siRNA group
(Fig. 6M and N). These results suggest that the increase in ATP produc-
tion via SMS1 and SMS2may contribute to the reduction of AMPK activ-
ity in liposomal SM(d18:1/16:0)-treated MMCs. Our results therefore
indicate that accumulation of SM(d18:1/16:0) may be an important
regulator of ATP levels in the glomeruli of the diabetic kidney and thus
contribute to the inhibition of AMPK in diabetic glomeruli (Dugan
et al., 2013; Sharma et al., 2008).
3.9. SM(d18:1/16:0) Increases Glycolytic Flux in Cultured Mesangial Cells
We then sought the source of ATP production by liposomal
SM(d18:1/16:0). Glucose consumption was signiﬁcantly reduced by
SMS2 or SMS1+ 2 siRNA in glomerularmesangial cells (Fig. 6O). Treat-
ment with liposomal SM(d18:1/16:0) signiﬁcantly increased glucose
consumption and was partially prevented by SMS1 or SMS2 siRNA
(Fig. 6O) and completely prevented by the co-transfection of both
SMS1 and SMS2 siRNAs (Fig. 6O). Lactate secretion was signiﬁcantly
increased by liposomal SM(d18:1/16:0), and was prevented by SMS2
or SMS1 + 2 siRNA (Fig. 6P). Extracellular glutamate was increased by
liposomal SM(d18:1/16:0), suggesting a reduction of glutamine utiliza-
tion in MMCs by liposomal SM(d18:1/16:0) (Fig. 6Q). ATP production
was signiﬁcantly inhibited by the addition of a glycolysis inhibitor 2-
Deoxy-D-glucose (2-DG) in untreated (P b 0.001) or control liposome
treated MMCs (P b 0.001) (Fig. 6R). However, in the liposomal
SM(d18:1/16:0)- and 2-DG-treated group, ATP production was further
reduced compared with the 2-DG or control liposome + 2-DG groups
(Fig. 6R). These results suggest that exogenous addition of SM(d18:1/
16:0) increases glycolysis-related ATP production.
4. Discussion
In the present study, using MALDI-MSI and AMM approaches, we
show that 1) the ATP/AMP and ATP/ADP ratio are increased in the glo-
meruli of diabetic mice compared with WT mice, 2) SM(d18:1/16:0)
is preferentially distributed in the glomeruli in normal human kidney,
and 3) SM(d18:1/16:0) is increased in the glomeruli of type 1 diabetic
and HFD-fed mice compared with controls. We also demonstrate by
in vitro studies using mesangial cells that AMPK–PGC1α is reduced
and ATP production is increased by the treatment with liposomal
SM(d18:1/16:0).
We have previously demonstrated that renal AMPK activity is re-
duced in mouse models of type 1 diabetes and obesity-related kidneydisease (conditions characterized by caloric excess states), and that
AMPK activation inhibits the progression of chronic kidney damage
(Decleves et al., 2011; Dugan et al., 2013). We have also reported that
activation of AMPK has a potent role in blocking proﬁbrotic signaling
via inhibition of high-glucose induced Smad4 nuclear translocation in
cultured murine mesangial cells (Zhao et al., 2015). In addition, we
have recently shown that the reducedmitochondrial function in diabet-
ic kidneys is associated with reduction of AMPK–PGC1α signaling
(Dugan et al., 2013). Although AMPK is a key player in regulating energy
balance and related to many signaling pathways in the progression of
DKD, little is known about the relationship of AMPK with ATP levels
in vivo, due to the difﬁculty in measurements in tissues. In addition, as
kidneys are complex organs and consist of many cell types and each
cell type may differentially regulate energy balance, the evaluation of
ATP/ADP and ATP/AMP ratios is difﬁcult to accurately assess in speciﬁc
compartments, such as the glomerulus. We show here that with
FTICR-MALDI-MSI, there is an increase in the ATP, ATP/AMP and ATP/
ADP ratio in diabetic glomeruli compared with WT glomeruli. It has
been reported that, in cultured rat mesangial cells, the extracellular
ATP levels are increased by high glucose, and in addition, ﬁbrosis-
related markers including ﬁbronectin and TGF-β are signiﬁcantly in-
creased by the addition of ATP (Solini et al., 2005). ATP levels are now
considered to be a promoter of inﬂammation (Cauwels et al., 2014),
and ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1),
which is expressed in the glomeruli and hydrolyze ATP and ADP to
AMP, is reported to prevent renal inﬂammation in the kidney of type
1 diabetic mice (Friedman et al., 2007). Based on our results it is likely
that enhanced ATP production is a characteristic of diabetic glomerular
disease.
We also demonstrate that intraglomerular SM(d18:1/16:0) is signif-
icantly increasedwith diabetes and a high-fat diet andmay be a key fac-
tor to drive the increased ATP levels. This is a surprising result as an
increase in SM(d18:1/16:0) has previously not been postulated to be a
direct consequence of hyperglycemia or a high fat diet in glomerular
cells. Alongside a direct effect of excess glucose, there may well be an
important contribution of SM(d18:1/16:0) to contribute to the en-
hanced ATP production. Importantly, SM(d18:1/16:0) increases ATP
production via activation of glycolytic pathway and thus may drive a
Warburg type effect in diabetic tissues. In addition, we also identiﬁed
that SMS2 expression was signiﬁcantly increased by the addition of
SM(d18:1/16:0) in MMCs, and ATP levels were signiﬁcantly decreased
by the knockdown of SMS2 or both SMS1 and 2, suggesting that SMS2
may play a central role in the regulation of ATP levels in MMCs. One of
the limitations of the study is the cell work was performed with one
cell line and additional glomerular cell types will need to be evaluated
in future studies.
It is notable that one week of HFD exposure is sufﬁcient to increase
SM(d18:1/16:0) in the renal glomeruli, suggesting that SM(d18:1/
16:0) accumulation could represent an early pathogenic event in
obesity-related kidney injury preceding glomerular disease. Moreover,
exogenous addition of liposomal SM(d18:1/16:0) reduces AMPK activi-
ty, and the addition of SMS1 and/or SMS2 siRNAs enhances AMPK activ-
ity in cultured mesangial cells. In fact, we have reported that AMPK
activity is reduced in the glomeruli as early as one week of high-fat
diet exposure (Decleves et al., 2011). These results suggest that there
is a link between accumulation of SM(d18:1/16:0) and reduction of glo-
merular AMPK activity with diabetes and obesity-related glomerular
disease.
It has been previously reported that SM(d18:1/16:0) is distribut-
ed in the cortex of mouse kidneys (Jones et al., 2014; Muller et al.,
2015) and Grove et al.(Grove et al., 2014) identiﬁed SM(d18:1/
16:0) as one of the lipids localized to glomeruli. Our study using
HSR-MALDI-MSI and AMM demonstrates that SM(d18:1/16:0) is
mainly localized in the glomeruli in both mouse and human kidney
cortex and that SM(d18:1/16:0) is increased in the glomeruli of
both HFD-fed mice and diabetic mice.
133S. Miyamoto et al. / EBioMedicine 7 (2016) 121–134Recently, the importance of SM in human diabetic nephropathy has
been suggested in a clinical study. Mäkinen VP et al. (Makinen et al.,
2012) reported that plasma SM is positively correlated with urinary al-
bumin excretion rate and negatively correlated with glomerular ﬁltra-
tion rate in patients with type 1 diabetes. In addition, they concluded
that, among lipids tested, SM is the strongest contributor to kidney dis-
ease. In terms of the importance of SM(d18:1/16:0), the results from the
Ludwigshafen Risk and Cardiovascular Health (LURIC) study are espe-
cially noteworthy (Sigruener et al., 2014). They applied electrospray
ionization tandemmass spectrometry (ESI MS/MS) to analyze the vari-
ous lipids including SM and ceramide species in plasma of the subjects
from the LURIC study (Sigruener et al., 2014). They found that, among
SM species tested, SM(d18:1/16:0) showed the strongest positive
association with mortality. In contrast, ﬁve other SM species displayed
an association with protective effect. Interestingly, ceramide(d18:1/
16:0) also shows similar positive association as the SM(d18:1/16:0)
(Sigruener et al., 2014). It is reported that intracellular C12:0 (d18:1/
12:0) ceramide and C12:0 SM are increased by the stimulation of
tumor necrosis factor (TNF) in dopaminergic neuroblastoma cells
(Martinez et al., 2012). Additionally, the supplementation of SM in cul-
ture medium led to increased secretion of IL-6 in response to treatment
with LPS (Chakraborty et al., 2013), suggesting that exogenous SM can
stimulate inﬂammation.
Sphingomyelinase is amajor SM-related enzyme,which catalyzes hy-
drolysis of SM to ceramide by cleaving a phosphocholine residue
(Taniguchi and Okazaki, 2014). On the other hand, SM is synthesized by
sphingomyelin synthase (SMS), which transfers the phosphorylcholine
moiety from phosphatidylcholine (PC) onto ceramide, producing SM
and diacylglycerol (DAG) (Hailemariam et al., 2008). Qureshi A et al.
(Qureshi et al., 2010) reported that SM(d18:1/16:0) is concentrated in
the Cryptococcus neoformans-infected mouse lung by mass spectrometry
imaging, and that inhibition of SMS impairs the killing ability of cultured
neutrophils. Yano et al. (2011) reported that SMS1 deﬁcient islet cells ex-
hibit reduced SM(d18:1/16:0) levels in isolated islets. SMS1deﬁcient islet
cells also exhibited upregulation of PGC1α expression and increased ex-
pression of markers for mitochondrial complex I (ND4 and ND6) and
complex IV (Cox1, 2, 3 and 4) suggesting the activation of mitochondrial
biogenesis. With the results of our present studies, it is likely that
increased SMS1 and SMS2 leads to accumulation of SM(d18:1/16:0) in
the diabetic glomeruli and that SM(d18:1/16:0) plays a key role in regu-
lating mitochondrial biogenesis and potentially inﬂammatory pathways
in diabetic glomeruli. We also demonstrate that SM(d18:1/16:0) stimu-
lates a key pro-ﬁbrotic pathway (Smad3) which has been linked to
reduced mitochondrial biogenesis in adipose tissue of obesity (Yadav
et al., 2011).
It remains controversial how SMase and/or SMS is regulated in the
organs of animals fed a HFD. It has been reported that three weeks of
HFD feeding induces a pronounced SM (including SM(d18:1/16:0))
accumulation in liver tissues, accompanied by decreased activity of
aSMase but increased nSMase activity (Chocian et al., 2010). Similarly,
Baranowski et al. (2007) reported the reduction of both aSMase and
nSMase activity in the heart of rats fed a HFD. In addition, Boini et al. re-
ported that 13weeks of HFD feeding reduced aSMase activity in adipose
tissues (Boini et al., 2010). However, to our knowledge, there are no re-
ports focused on the regulation of SMase and SMS in the kidney of HFD-
fed mice. In our experiment, we found that the accumulation of SM in
the glomeruli of HFD-fed mice may be due to reduction of nSMase and
increased SMS1 level in the glomeruli.
In conclusion, by utilizing HSR-MALDI-MSI, we have found accumu-
lation of SM(d18:1/16:0) in the glomeruli of two different mouse
models for CKD. Increased ATP levels in the diabetic glomeruli and
MMCs treatedwith liposomal SM(d18:1/16:0)may contribute to inhib-
it AMPK activity and promote ﬁbrosis-related protein expression in the
glomeruli. SM(d18:1/16:0) primarily stimulates ATP production via en-
hanced glucose transport and aerobic glycolysis. Our data demonstrates
an important link between SM(d18:1/16:0), and the regulation ofglucose metabolism in high fat diets, diabetes and kidney diseases.
Further studies are required to establish whether SM is a necessary
mediator to increase ATP/AMP in vivo. These ﬁndings provide a
novel understanding of the regulation of ATP production in the
pathogenesis of caloric-induced CKD. The inhibition of SM(d18:1/
16:0) synthesis may lead to novel therapeutic targets for the treat-
ment of caloric-induced CKD.
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